An open, phase III study of lanreotide (Somatuline PR) in the treatment of acromegaly.

Lin JD, Lee ST, Weng HF

Endocrine journal1 Feb 1999Cited by 3 (Europe PMC)

PMID10426587DOI10.1507/endocrj.46.193PepBankPUB-10426587

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanNon-randomized trialEfficacy outcome
In postoperative acromegaly, lanreotide decreased mean GH from 24.8 +/- 12.5 to 6.9 +/- 3.3 ng/ml after 12 weeks.
In plain wordsIn postoperative acromegaly, lanreotide decreased GH from baseline after 12 weeks.
Peptide
Lanreotide
Outcome
DecreaseSerum GH
Study
n = 6
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
30 mg every 2 weeks · intramuscular · 12 weeksAs given in this study (human).
Measurements
Mean GH
24.8 ng/ml
before treatment; +/- 12.5 (SEM)
Mean GH
6.9 ng/ml
after 12 weeks; +/- 3.3 (SEM)
Source sentences
Summary
After 12 weeks of treatment, mean (+/- SEM) GH levels decreased from 24.8 +/- 12.5 to 6.9 +/- 3.3 ng/ml and mean serum IGF-I levels decreased from 689 +/- 282 to 430 +/- 216 ng/ml.
2 context sentences(design, population, supporting numbers)
Summary · context
The aim of this open Phase III study was to investigate the clinical efficacy of lanreotide in the treatment of six acromegalic patients with a mean age of 44 +/- 13 yr including two patients with diabetes mellitus.
Summary · context
Lanreotide was given intramuscularly every 2 weeks at a fixed dose of 30 mg for 12 weeks.
Report a problemFND-1042658701
02HumanNon-randomized trialEfficacy outcome
In postoperative acromegaly, lanreotide decreased mean IGF-I from 689 +/- 282 to 430 +/- 216 ng/ml after 12 weeks.
In plain wordsIn postoperative acromegaly, lanreotide decreased IGF-I from baseline after 12 weeks.
Peptide
Lanreotide
Outcome
DecreaseSerum IGF-I
Study
n = 6
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
30 mg every 2 weeks · intramuscular · 12 weeksAs given in this study (human).
Measurements
Mean serum IGF-I
689 ng/ml
before treatment; +/- 282 (SEM)
Mean serum IGF-I
430 ng/ml
after 12 weeks; +/- 216 (SEM)
Source sentences
Summary
After 12 weeks of treatment, mean (+/- SEM) GH levels decreased from 24.8 +/- 12.5 to 6.9 +/- 3.3 ng/ml and mean serum IGF-I levels decreased from 689 +/- 282 to 430 +/- 216 ng/ml.
2 context sentences(design, population, supporting numbers)
Summary · context
The aim of this open Phase III study was to investigate the clinical efficacy of lanreotide in the treatment of six acromegalic patients with a mean age of 44 +/- 13 yr including two patients with diabetes mellitus.
Summary · context
Lanreotide was given intramuscularly every 2 weeks at a fixed dose of 30 mg for 12 weeks.
Report a problemFND-1042658702
03HumanNon-randomized trialSafety outcome
In postoperative acromegaly, ultrasonography showed no gallbladder stones before or after lanreotide treatment.
In plain wordsIn postoperative acromegaly, scans showed no gallbladder stones before or after lanreotide treatment.
Peptide
Lanreotide
Outcome
Not applicableGallbladder stones
Study
n = 6
Outcome group
Adverse events · Gastrointestinal
Studied dose
30 mg every 2 weeks · intramuscular · 12 weeksAs given in this study (human).
Source sentences
Summary
Abdominal ultrasonographic examinations showed no gallbladder stone or bile sand formation before or after the treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
The aim of this open Phase III study was to investigate the clinical efficacy of lanreotide in the treatment of six acromegalic patients with a mean age of 44 +/- 13 yr including two patients with diabetes mellitus.
Summary · context
Lanreotide was given intramuscularly every 2 weeks at a fixed dose of 30 mg for 12 weeks.
Report a problemFND-1042658703
04HumanNon-randomized trialSafety outcome
In postoperative acromegaly, ultrasonography showed no bile sand before or after lanreotide treatment.
In plain wordsIn postoperative acromegaly, scans showed no bile sand before or after lanreotide treatment.
Peptide
Lanreotide
Outcome
Not applicableBile sand
Study
n = 6
Outcome group
Adverse events · Gastrointestinal
Studied dose
30 mg every 2 weeks · intramuscular · 12 weeksAs given in this study (human).
Source sentences
Summary
Abdominal ultrasonographic examinations showed no gallbladder stone or bile sand formation before or after the treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
The aim of this open Phase III study was to investigate the clinical efficacy of lanreotide in the treatment of six acromegalic patients with a mean age of 44 +/- 13 yr including two patients with diabetes mellitus.
Summary · context
Lanreotide was given intramuscularly every 2 weeks at a fixed dose of 30 mg for 12 weeks.
Report a problemFND-1042658704
05HumanNon-randomized trialSafety outcome
In postoperative acromegaly, three patients who did not receive octreotide had mild gastrointestinal adverse effects, such as mild abdominal pain and diarrhea, during lanreotide treatment.
In plain wordsIn postoperative acromegaly, three patients not given octreotide had mild digestive side effects such as abdominal pain and diarrhea during lanreotide treatment.
Peptide
Lanreotide
Outcome
Not applicableMild gastrointestinal adverse effects
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
30 mg every 2 weeks · intramuscular · 12 weeksAs given in this study (human).
Measurements
Patients with mild gastrointestinal adverse effects
3 patients
patients who did not receive octreotide; denominator not stated
Source sentences
Summary
Three of the patients who did not receive octreotide presented with manifestations of mild gastrointestinal adverse effect such as mild abdominal pain and diarrhea.
2 context sentences(design, population, supporting numbers)
Summary · context
The aim of this open Phase III study was to investigate the clinical efficacy of lanreotide in the treatment of six acromegalic patients with a mean age of 44 +/- 13 yr including two patients with diabetes mellitus.
Summary · context
Lanreotide was given intramuscularly every 2 weeks at a fixed dose of 30 mg for 12 weeks.
Report a problemFND-1042658705

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.